Jay S. Dela Cruz - Concepedia

Author

Jay S. Dela Cruz

University of California, Los Angeles

Also Known As

J. S. Dela Cruz, Jay S Dela Cruz, Jay S. Dela Cruz, Jay S.Dela Cruz, Jay Soriano Dela Cruz

Publications

397

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles

About

Jay S. Dela Cruz is an author at University of California, Los Angeles specializing in immunology, immunotherapy, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	268
2	Immunology	7	7	268
3	Cell Biology	5	5	182
4	Autoimmunity	2	2	101
5	Allergy	1	1	61

Jay S. Dela Cruz

Publications

351

Citations

H-Index

Page 1

	Year	Citations
Recombinant Anti-Human HER2/ <i>neu</i> IgG3-(GM-CSF) Fusion Protein Retains Antigen Specificity and Cytokine Function and Demonstrates Antitumor Activity Jay S. Dela Cruz, K. Ryan Trinh, Sherie L. Morrison, The Journal of Immunology	2000	83
An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells Patrick P. Ng, Jay S. Dela Cruz, David N. Sorour, Proceedings of the National Academy of Sciences ImmunologyCell DeathImmunologic MechanismAntigen ProcessingVarious Molecules	2002	78
Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody–cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice Jay S. Dela Cruz, Suk Ying Lau, Ernesto M Ramirez, Vaccine VaccinationCross-protectionProtein VaccinationVaccine DevelopmentAllergy	2003	61
A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors Manuel L. Penichet, Jay S. Dela Cruz, Seung-Uon Shin, Human Antibodies Radiation OncologyCancer ImmunosurveillanceAnti-her2/neu Igg3-MedicineImmunology	2001	42
Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors Gustavo Helguera, Jay S. Dela Cruz, Christine Lowe, Vaccine VaccinationProtective Immune ResponseImmunologyTumor ImmunityTherapeutic Vaccine	2005	25
Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein Jay S. Dela Cruz, Sherie L. Morrison, Manuel L. Penichet Vaccine VaccinationTumor ImmunologyCancer ImmunosurveillanceAnti-her2/neu Igg3-Immunology	2005	23
Mechanism of Antitumor Activity of a Single-Chain Interleukin-12 IgG3 Antibody Fusion Protein (mscIL-12.her2.IgG3) Lisan S. Peng, Manuel L. Penichet, Jay S. Dela Cruz, Journal of Interferon & Cytokine Research Tumor ImmunologyAntitumor ActivityCancer ImmunosurveillanceImmunologyTumor Immunity	2001	21
Anti-HER2/neu IgG3–(IL-2) and anti-HER2/neu IgG3–(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: Implications in immunotherapy and vaccination strategies Jay S. Dela Cruz, Kamh Ryan Trinh, Antoni Ribas, Molecular Immunology VaccinationAnti-her2/neu Igg3–Her2/neu ProcessingImmunologyTumor Immunity	2005	18

Page 1